Neurodoc's Blog : Latest entries

The percentage price oscillator as a measure of overbought/oversold I believe I was overestimating--market kept selling--selling--selling, until today (5/21).  We got some nice bullish engulfing patterns, suggesting the long-anticipated short-term rally may be at hand, but then I think there will be some backing and filling before there is a more sustained rally, or worse, a continued downtrend.  The signs in the NYSE bullish percent index that I think would point to a more powerful ra…

US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for ReviewToday Biogen Idec (NASDAQ: BIIB) announced that U.S. and EU regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) has accepted Biogen Idec's New Drug Application (NDA) for marketing a…

Hedge on would be in place again except there are candlestick hammers all over the place in stocks, averages and sectors (but this sign needs confirmation) plus the 60,5 price percentage oscillator of the equities only put call ratio is now oversold (IMO) at <-15--so I'm looking for a rally to begin shortly and last shortly, preparing to hedge about 5 days after it starts unless something dramatically changes for the better (e.g. an extremely strong rally).  Buying now but holding the re…

Whole Foods Markets Inc. (WFM) reported a forecast-beating 31% rise in fiscal-second-quarter profit as the upmarket U.S. grocery store chain pledged to pass on the cost of easing food-inflation pressures to shoppers.
The Austin, Texas organic foods specialist has become the largest U.S. pure-play grocery operator by market value, and delivered a 9.5% rise in comparable-store sales for the quarter, boosting its full-year view well above the sector average.
The urban-mythical home of the $…

Les Masonson's "Buy Don't Hold" blog hovered on a buy signal this weekend that appears to have occurred today.  While the bullish percent index MA I use hasn't crossed over yet, I follow his analysis as well.  Also, other technicians such as John Murphy and Tom Bowley remain bullish, the latter noting that over the past 25 years May (particularly the first week) has been bullish for small stocks--i.e. along with other recent commentary the "sell in May and go away" adage may be overrat…

Since March 8, skirted a hedge-off shift that didn't happen.  I'm trying to take quick profits on stock screen stocks that look to have a good set up, go up a bit and then show probable reversal.  Stocks quietly cruising I'm keeping fairly tight stops except long-term holds (WFM, UNFI etc).  Getting near the historical crummy 6 months.

Crossover again of bullish percent index MA, except the PPO just became overbought, which at this stage of the rally I believe may portend a downturn of unclear magnitude, so hedge stays on for now.

Crossover of the bullish percent index MA occurred today (3/7) prompting inverse ETF (shorting)  purchases to hedge long positions.  3-4 distribution days have occurred recently in major averages.  The PPO is also not oversold.  Of course, whipsaw with resumption of uptrend is possible, but I'm just going with perceived probability of further market declines.

RUT and SML broke support Fri and likely then will go lower.  Trend pundits I follow are giving mixed signals.  The bullish percent indicator I follow is still in an uptrend, but a MA crossover looks imminent.  I've put in stop-limit orders on my price/cash flow-sales screen stocks (generally small stocks) and see what develops.

Look for Levadex to be FDA approved later in March or possibly later.  The orally inhaled DHE formulation for aborting a migraine looks very promising.  Non-approval by FDA at this point seems inconceivable.  I don't know if the patented inhaler (improved delivery v. older inhalers) would extend inhaler patent to other inhaled drugs.  I also don't know if anticipated approval is already built into the stock price, but I anticipate utilization post-approval will exceed current…